Clinical and pharmacoeconomic profile of COPD patients with FEV1 50—60% predicted: Pilot study on the impact of the extended indication of ICS/LABA

Therapeutic Advances in Respiratory Disease

Volumn 3, Issue 2, 2009, Pages 51-58

  Dal Negro, Roberto Walter ^a,b   Bonadiman, Luca ^a   Turati, Claudio ^b   Turco, Paola ^a  

^a CESFAR   (Italy)

^b Ospedale Orlandi   (Italy)

Author keywords

COPD; GOLD; guidelines; ICS LABA; pharmacoeconomics

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADULT; BRONCHODILATOR AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; YOUNG ADULT;

EID: 67449155316     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809335159     Document Type: Article

References (16)

1. Aaron, S., Fergusson, D., Marks, G.B., Suissa, S., Vandemheen, L., Doucette, S. et al. (2008) Counting analysis and reporting exacerbations of COPDin randomised controlled trials. Thorax 63: 122-128.
2. Calverly, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Lones, P.W. et al. (2007) TORCH investigators - salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
3. Calverly, P.M., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A. et al. for the Tristan Study Group (2003) Combining sameterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a arandomized controller trial. Lancet 361: 449-456.
4. Celli, B.R., Thomas, N.E., Anderson, J.A., Ferguson, G.T., Jenkins, P.W., Vestbo, J. et al. (2008) Effects of pharmacotherapy on rate of decline of lung funtion in chronic obstructive pulmonary disease: results from the TORCH Study. Am J Respir Crit Care Med 178: 332-338.
5. Dal Negro, R., Zoccatelli, O., Pomari, C., Turco, P., Girelli-Bruni, E. (1984) Gestione automatizzata di alcuni flussi informativi nell'ambito della patologia respiratoria. Proceedings of the 7th SIFPR National Congress, pp. 1007-1022.
6. Dal Negro, R.W., Pomari, C., Tognella, S. and Micheletto, C. (2003) Salmeterol and fluticasone 50mcg/250mcg bid in combination provides a better long-term control than salmeterol 50mcg bid alone and placebo in COPD patients already treated wiyh theophylline. Pulm Pharmacol Ther 16: 241-246.
7. Fletcher, C.M. and Peto, R. (1977) The natural history of chronic airflow obstruction. BMJ 1: 1645-1648.
8. Global Initiative for Chronic Obstructive Lung Disease (2006) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com
9. Istat (2008) Le cento statistiche per il Paese, Maggio.
10. Kardos, P., Wenker, M., Glaab, T. and Vogelmeier, C. (2007) Impact of salmeterol/fluticasone propionate versus salmetrol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 144-149.
11. Suissa, S., Ernst, P., Vandeheen, K.L. and Aaron, S.D. (2008) Methodological issues in therapeutic trials of COPD. Eur Respir J 31: 927-933.
12. Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S. et al. (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: 74-81.
13. Viegi, G., Scognamiglio, A., Baldacci, S., Pistelli, F. and Carrozzi, L. (2001) Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 68: 4-19.
14. Wedzicha, J.A., Calverly, P.M., Seemungal, T.A., Hagan, G., Ansari, Z. and Stockley, R.A. (2008) The prevention of chronic obstructive pulmonary
15. disease exacerbations by salmetero/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-28.
16. Wouters, E.F., Postma, D.S., Fokkens, B., Hop, W.C., Prins, J., Kuipers, A.F. et al. (2005) Withdrawals of fluticasone propionate from combined salmeterol/ fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled study. Thorax 60: 480-487.